-
Capital, M&A & Industry Strategy1 month agoEyeing post-Dupixent years, Regeneron, Sanofi expand immunology collaboration
BIOCENTURY | DEALSEYEING POST-DUPIXENT YEARS, REGENERON, SANOFI EXPAND IMMUNOLOGY COLLABORATIONThe longtime partners bring four more products into their shared portfolio, including a clinical, long-acting IL-13 inhibitor...
-
Global Biotechnology & Pharmaceutical Markets1 month agoLive from Amsterdam: Grand Rounds Europe’s top takeaways
BIOCENTURY | DISCOVERY & TRANSLATIONLIVE FROM AMSTERDAM: GRAND ROUNDS EUROPE’S TOP TAKEAWAYSOskar Slotboom, Ruud Smits, and Dinko Valerio join the BioCentury team on a special edition of...
-
Regulatory Intelligence & Drug Approvals1 month agoWitty, Sharpless join Hatteras. Plus: PhRMA picks Cantor to succeed Ubl
BIOCENTURY | MANAGEMENT TRACKSWITTY, SHARPLESS JOIN HATTERAS. PLUS: PHRMA PICKS CANTOR TO SUCCEED UBLAnd a CEO change at Pharming; FDA recruiting people with expertise for advisory...
-
Regulatory Intelligence & Drug Approvals1 month agoI-DXd withdrawal thins October PDUFA calendar
BIOCENTURY | DATA BYTEI-DXD WITHDRAWAL THINS OCTOBER PDUFA CALENDARFive FDA decisions remain after BLA withdrawal and two sNDA approvals
-
Capital, M&A & Industry Strategy1 month agoNovo gets shot at weekly obesity pill as Hengrui gets another MNC deal
BIOCENTURY | DEALSNOVO GETS SHOT AT WEEKLY OBESITY PILL AS HENGRUI GETS ANOTHER MNC DEALNovo adds once-weekly oral GLP1R/GIPR dual agonist for $300M up front
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoFour-year data raise durability questions for uniQure’s Huntington gene therapy
BIOCENTURY | PRODUCT DEVELOPMENTFOUR-YEAR DATA RAISE DURABILITY QUESTIONS FOR UNIQURE’S HUNTINGTON GENE THERAPYSmaller effect on composite endpoint clouds outlook, while functional capacity results preserve case for...
-
Drug Discovery & Therapeutics1 month agoAstraZeneca buys stake in Summit, plans combo trials pairing ADCs with bispecific
BIOCENTURY | DEALSASTRAZENECA BUYS STAKE IN SUMMIT, PLANS COMBO TRIALS PAIRING ADCS WITH BISPECIFIC$2B equity investment signals commitment to testing conjugated therapies, including CLDN18.2-targeted ADC, with...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoCAR T start-up Link Cell names BMS, SystImmune vet Jie D’Elia CEO
BIOCENTURY | MANAGEMENT TRACKSCAR T START-UP LINK CELL NAMES BMS, SYSTIMMUNE VET JIE D’ELIA CEOIovance alum Friedrich Graf Finckenstein is CMO, co-founder Brian Slingerland becomes Executive Chair
-
Capital, M&A & Industry Strategy1 month agoIgA nephropathy, Overton hearing, reverse mergers’ new look — a BioCentury podcast
BIOCENTURY | PRODUCT DEVELOPMENTIGA NEPHROPATHY, OVERTON HEARING, REVERSE MERGERS’ NEW LOOK — A BIOCENTURY PODCASTRecent approvals, validated biomarkers and FDA flexibility have turned IgA nephropathy from...
-
Global Biotechnology & Pharmaceutical Markets1 month agoMerck turns to China-based SciBrunch for KRAS program, pays $400M up front: Deals Report
BIOCENTURY | DEALSMERCK TURNS TO CHINA-BASED SCIBRUNCH FOR KRAS PROGRAM, PAYS $400M UP FRONT: DEALS REPORTPlus: A pair of deals for Roche, and more
Widespread atropine use fails to sway FDA advisors on Sydnexis data
At least 11 PDUFAs on FDA’s November docket
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
